Empiric therapy of community-acquired pneumonia: guidelines for the perplexed?
This article discusses the key clinical aspects of empiric therapy of community-acquired pneumonia (CAP). Antibiotic selection, severity of CAP, single vs multiple pathogens, pharmacokinetic considerations, antibiotic resistance, i.v. vs oral antibiotic therapy for CAP, oral therapy for non-ICU hospitalized patients with CAP, beta-lactams, macrolides, ketolides, doxycycline, respiratory quinolones, and pharmacoeconomic implications are discussed.
Cunha
Burke A
BA
Infectious Disease Division, Winthrop-University Hospital, Mineola, NY 11501, USA.
D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D017714:Community-Acquired Infections / Q000188:drug therapy; D024881:Drug Resistance, Bacterial; D006760:Hospitalization; D006801:Humans; D018942:Macrolides / Q000627:therapeutic use; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D015363:Quinolones / Q000627:therapeutic use; D012720:Severity of Illness Index
D000900:Anti-Bacterial Agents; D018942:Macrolides; D015363:Quinolones